Medical Chronicle November/December 2013 | Page 35
Living life,
without
compromise
Effective pain relief and increased WOMAC function score1
• Equally effective as comparators* in treating arthritic
symptoms in OA, RA and AS2
Effective gastroprotection 3,4
• With a built-in PPI3
Least likely to increase CV risk5
• Lower risk of CV events with naproxen vs. other
traditional NSAIDS and COX-2 inhibitors 6
Sequential delivery 3
• Immediate-release esomeprazole followed by
EC naproxen3
• In a single convenient tablet3
OA – Osteoarthritis
PPI – Proton pump inhibitor
COX - Cyclo-oxygenase
RA – Rheumatoid ar thritis
CV – Cardiovascular
EC – Enteric coated
AS – Ankylosing spondylitis
NSAID – Non-Steroidal Anti-Inflammatory Drug
* Comparators Include: naproxen, ibuprofen, diclofenac,
ketoprofen, etoricoxib, fixed-dose diclofenac sodium plus
misoprostol
Effective pain relief with built-in
gastroprotection 3
References:
1. Hochberg MC, Fort JG, Svensson O, et al. Fixed-dose combination of enteric-coated naproxen and immediate-release esomeprazole has comparable efficacy to celecoxib for knee osteoarthritis: two randomized
trials. Curr Med Res Opin 2011;27(6):1243-1253. 2. Datto C, Hellmund R, Siddiqui MK. Efficacy and tolerability of naproxen/esomeprazole magnesium tablets compared with non-specific NSAIDs and COX-2 inhibitors:
a systematic review and network analyses. Rheum Res & Rev 2013;5:1-19. 3. Wang-Smith L, Fort J, Zhang Y, et al. Pharmacokinetics and relative bioavailability of a fixed-dose combination of enteric-coated naproxen
and non-enteric-coated esomeprazole magnesium. J Clin Pharmacol 2012;52(5):670-680. 4. Goldstein JL, Hochberg MC, Fort JG, et al. Clinical trial: the incidence of NSAID-associated endoscopic gastric ulcers in
patients treated with PN 400 (naproxen plus esomeprazole magnesium) v 2?V?FW&?2?6?FVB?&??V????R???V?B?&?6??F?W"#?3"?2??C?C2?R??4vWGF?v???V?'?B?6&F??f67V?"&?6?v?F?????7FW&??F???F???f???F?'?G'Vw3?7?7FV?F?2&Wf?Wr?b?V?F????&6VB6??G&???VB?'6W'fF????7GVF?W2???2?VF?6??R#?????????b?&?7F???????VF???V?B"?WB??6?F??6??6V?7W2wV?FV??W2?????r?FW&????7FW&??F??F???f???F?'?G'VrF?W&??BF?R?VVBf?"v7G&?&?FV7F????&V?Vf?G2fW'7W2&?6?2???V?B?&?6??F?W"#??#??C??C?b??3Bd???d? *?S?#?r?F&?WB??&Vr????CR?2??s??4???4?D????V6?F&?WB6??F??2S?r?&??V??B#?rW6??W&???R?2W6??W&???R?v?W6?V?G&???G&FR????$?4???t?4?4?54?d?4D????2??F?&?WV?F?72??F???f???F?'?vV?G2????D?4D???3?7??F??F?2&V?Vb??F?RG&VF?V?B?b&?WV?F??B'F?&?F?2??7FV?'F?&?F?2?B???6??p?7??G??F?2???F?V?G2?VVF??r&?F???V???&?F?'2F?&VGV6RF?R&?6??bFWfV????r????7FW&??F??F???f???F?'?G'Vw2??4?G2?76?6?FVBv7G&?2?B??"GV?FV??V?6W'2?d???d? *??2?&Vv?7FW&VBG&FV?&??bF?R7G&?V?V6w&?W?b6????W2?f?"gV??FWF??2&V?F??rF?????f?&?F????V?F???VB&?fR?V6R&VfW"F?F?R&?fVB6?vR??6W'B?7G&?V?V6?&?6WWF?6?0??G???FB?&Vr??????"?S?SB?r?'V??F??r"???'F?F?v?2?ff?6R&??rvV?&v??7&W66V?BvW7B?''??7F???#??&?fFR&r?#2?''??7F???##?FVâ??s?r?c?f????s?r?c??wwr?7G&?V?V6?6????W??'?FFS??V?R#R???r???d??b?2??